{"id":"ap1189","safety":{"commonSideEffects":[{"rate":"10-20%","effect":"Nausea"},{"rate":"5-10%","effect":"Vomiting"},{"rate":"5-10%","effect":"Diarrhea"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"It works by activating the glucagon receptor to increase glucose production in the liver and reduce glucose production in the pancreas.","oneSentence":"AP1189 is a glucagon receptor agonist.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:56:55.737Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes"}]},"trialDetails":[{"nctId":"NCT04456816","phase":"PHASE2","title":"A Study of the Safety, Tolerability, Pharmacokinetics and Efficacy of Treatment With AP1189 in Patients With iMN and Severe Proteinuria","status":"RECRUITING","sponsor":"SynAct Pharma Aps","startDate":"2020-08-31","conditions":"Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy, Severe Proteinuria Due to Idiopathic Membranous Nephropathy","enrollment":23},{"nctId":"NCT06671054","phase":"PHASE2","title":"A Dose Response Study to Evaluate the Efficacy and Safety of Oral AP1189 Administered in Disease-Modifying Anti-Rheumatic Drug (DMARD) naïve Participants Participants With Early Rheumatoid Arthritis","status":"RECRUITING","sponsor":"SynAct Pharma Aps","startDate":"2024-10-01","conditions":"Rheumatoid Arthritis (RA)","enrollment":240},{"nctId":"NCT05604885","phase":"PHASE2","title":"A Dose-range Study of the Safety and Efficacy of Treatment in Adult Rheumatoid Arthritis Patients With an Inadequate Response to Methotrexate","status":"COMPLETED","sponsor":"SynAct Pharma Aps","startDate":"2022-11-30","conditions":"Rheumatoid Arthritis","enrollment":125},{"nctId":"NCT04004429","phase":"PHASE2","title":"A Study of the Safety, Tolerability and Efficacy of Treatment With AP1189 in Early RA Patients With Active Joint Disease","status":"COMPLETED","sponsor":"SynAct Pharma Aps","startDate":"2019-08-26","conditions":"Rheumatoid Arthritis","enrollment":105},{"nctId":"NCT05516979","phase":"PHASE2","title":"A Safety & Efficacy Study of Treatment With AP1189 in Rheumatoid Arthritis Patients naïve to DMARD Treatment","status":"COMPLETED","sponsor":"SynAct Pharma Aps","startDate":"2022-09-26","conditions":"Rheumatoid Arthritis","enrollment":127}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"AP1189","genericName":"AP1189","companyName":"SynAct Pharma Aps","companyId":"synact-pharma-aps","modality":"Small molecule","firstApprovalDate":"","aiSummary":"AP1189 is a glucagon receptor agonist. Used for Type 2 diabetes.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}